Collaborating in new and dynamic ways with innovators across the health landscape is very important in our efforts to improve patients’ lives. Our approach is creative yet disciplined, focusing on specific opportunities and the right partners to accelerate innovative science, improve operations and find better ways to deliver needed therapies. Increasingly, this has led to unique, focused alliances with our global pharmaceutical peers.

“Over the last several years the health care landscape has seen tremendous scientific breakthroughs happening at Pfizer and beyond our walls. There are exciting opportunities to collaborate in new ways to augment our own discovery efforts. We look to bring together the best resources so that we can get the most impactful treatments and vaccines to patients, faster — it’s what motivates us every day.”

— Mikael Dolsten, M.D., Ph.D.
President, Worldwide Research and Development
Our immuno-oncology alliance with Merck KGaA, Darmstadt, Germany continues to move forward quickly and demonstrate how effectively we are working together. Our co-development of avelumab, the fully human anti-PD-L1 IgG1 monoclonal antibody, continues to reach and surpass new milestones.

**Investigational Antibody Avelumab Designated Breakthrough Therapy, Advances in Trials**

In 2015, the U.S. Food and Drug Administration granted Breakthrough Therapy, Orphan Drug, and Fast Track review designations for avelumab as a potential treatment for patients with metastatic Merkel cell carcinoma who have progressed after at least one previous chemotherapy regimen. These designations represent significant milestones in helping us bring this potentially important therapy to patients as quickly as possible. There is currently no therapy approved specifically for the treatment of metastatic Merkel cell carcinoma, a rare and aggressive type of skin cancer.

If approved, the first potential commercial launch of avelumab, for Merkel cell carcinoma, is anticipated in 2017. We anticipate approval of indications in other tumor types at the rate of at least one each year through 2022. The alliance initiated six pivotal trials in 2015 including: NSCLC 2L, NSCLC 1L, metastatic gastric cancer 3L, metastatic gastric cancer 1L, platinum-resistant or refractory ovarian cancer, and urothelial cancer 1L maintenance.
Co-promoting Xalkori®

As part of the agreement with Merck KGaA, Darmstadt, Germany, the alliance is co-promoting Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor Xalkori® (crizotinib) in a number of markets including the U.S., Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the U.K.). The agreement showcases our shared commitment to establishing a combined oncology sales organization in key markets in advance of the potential launch of avelumab-based treatment regimens in the future. Xalkori is the first ALK inhibitor approved in the U.S., Japan and the European Union and is supported by three positive global randomized trials in the first- and second-line ALK-positive metastatic non-small cell lung cancer treatment settings.

DEVELOPING NEXT-GENERATION MANUFACTURING: PORTABLE, CONTINUOUS, MINIATURE AND MODULAR

We have entered into a multi-year collaboration with GlaxoSmithKline PLC (GSK) to develop a next-generation design of our portable, continuous, miniature and modular (PCMM) prototype for oral solid dose pharmaceutical development and manufacturing. Pfizer’s current PCMM prototype is an autonomous pod that may be quickly shipped from location to location and readily brought online to create a fully functional module that is compliant with industry-standard good manufacturing practice guidelines.

Together with GEA Group, G-CON Manufacturing and GSK, which have notable technical and regulatory experience in continuous processing, we will conduct coordinated experiments to create the next-generation design of our current PCMM prototype. This collaboration expands upon Pfizer’s existing collaboration with GEA and G-CON Manufacturing, which resulted in the design of the prototype unit currently at Pfizer’s labs in Groton, Connecticut, U.S.

The pharmaceutical industry has been trending toward lower volume products, driven by an increased focus on precision medicine approaches to develop and commercialize new therapies. This creates a need for smaller, more flexible continuous processing technologies.

PCMM has the potential to transform the current biopharmaceutical industry standard of using batch processing to manufacture tablets and capsules from powders — an oftentimes complex process that requires large, dedicated manufacturing facilities. The PCMM continuous process takes only minutes from the addition of raw materials to the completion of finished tablets or capsules.
"We believe coupling Pfizer’s industry-leading development and manufacturing capabilities with GSK’s experience and expertise in continuous processing has the potential to lead to a superior technology, thereby allowing us to more quickly and efficiently bring therapies to patients."

— Rod MacKenzie
Senior Vice President, PharmaTherapeutics Research and Development

TRANSFORMING THE WAY THE PHARMACEUTICAL INDUSTRY MAKES TABLETS

Transforming the Way the Pharmaceutical Industry Makes Tablets

The Move to Portable, Continuous, Miniature and Modular Manufacturing

TODAY
Batch operations make drugs from powder to tablet in weeks or months
Complex process with large, dedicated manufacturing facility

TOMORROW
Continuous operations make drugs from powder to tablet in minutes
Miniaturized equipment fits in portable, mobile facility

First-of-a-kind System Offers Many Benefits over Current Technology

- Tablets in minutes vs weeks or months
- 60-70% Smaller
- Implementation in <1 year vs 2-3 years
- Same equipment for development, clinical trials and commercial manufacturing
- Continuous quality monitoring during production

PORTABLE PRODUCTION FACILITIES MEAN MEDICINES DELIVERED FASTER TO PATIENTS IN NEED

**TRANSFERABLE**
Modular, enclosed units called PODs ship by truck and can quickly be assembled to create a fully functional GMP-legal manufacturing space

**FLEXIBLE**
Same equipment in all stages allows for automated production lots based on market demand

**FAST TO MARKET**
Customized production lots and re-deployable, modular PODs get medicines to patients when and where they are needed
IN PHASE 3 WITH ELI LILLY

Pfizer and Eli Lilly and Company have resumed the Phase 3 clinical program for tanezumab, following a decision by the U.S. Food and Drug Administration to lift the partial clinical hold that had been in place for tanezumab and all other anti-nerve growth factor antibodies since 2012 due to adverse changes in the sympathetic nervous system of mature animals. (Studies in terminal cancer pain were allowed to proceed.) The decision followed a review of a robust body of nonclinical and clinical data characterizing the sympathetic nervous system response to tanezumab.

Tanezumab is a humanized monoclonal antibody that selectively targets and binds to nerve growth factor, a regulator of pain processing and sensitivity, thereby inhibiting this protein from activating pain-signaling neurons. Prior clinical studies of more than 11,000 patients compared tanezumab to placebo and other select commonly used pain medicines.

“We’re pleased to work with Eli Lilly to advance the Phase 3 program for tanezumab. If approved, tanezumab may offer an innovative, non-narcotic treatment for patients with certain pain conditions.”

— Ken Verburg, Ph.D.
Senior Vice President and Head of Global Medicines Development

PROJECT DATA SPHERE COLLABORATION IN ONCOLOGY

Sharing data to speed cancer research, Pfizer is helping to usher in a new era of data transparency. We have joined with industry and research partners to challenge traditions and collaborate in new ways to help cancer patients get the greatest possible benefit from our vast collection of clinical trial data. Project Data Sphere is an independent not-for-profit data-sharing initiative led by the CEO Roundtable on Cancer Life Sciences Consortium. The overarching goal is to foster collaboration across companies and academia to advance research that has the potential to improve outcomes for cancer patients. Pfizer has contributed data from studies in breast, lung, prostate and colon cancer that had already been analyzed and used. Doing so gives the data a second life, allowing other researchers to use them in different ways that may lead to important potential new insights and discoveries. Researchers around the world will have access to these platforms, with the hope that they will then generate new research hypotheses and accelerate innovation.

“Aggregating these data sets empowers cancer researchers to formulate novel research hypotheses and interrogate data in new ways.”

— Ronit Simantov
Vice President, Oncology Global Medical Affairs

~1 IN 5
NEARLY 1 IN 5 ADULTS SUFFER FROM CHRONIC PAIN.
NEXT-GENERATION SEQUENCING-BASED COMPANION DIAGNOSTICS COLLABORATION

With the rise of targeted therapies, a practical method for matching cancer patients with specific drug candidates is needed to enable the evolution of precision medicine. As such, Pfizer has entered into a long-term collaboration with Thermo Fisher Scientific and Novartis to develop a multi-marker, universal next-generation sequencing (NGS) oncology test panel that will serve as a companion diagnostic (CDx) initially for non-small cell lung cancer (NSCLC) followed by other cancer indications across multiple development programs. NGS enables testing of multiple genes simultaneously from a single tumor sample to help to identify their unique genetic profile. The ultimate goal is to use this information to guide the appropriate therapy choice among multiple drug candidates. NGS also has the potential to improve safety, effectiveness and health outcome of patients via targeted risk stratification and tailored treatment approaches. The collaboration, focused on a universal testing approach, could also accelerate the development and registration of several new NSCLC drugs and other drug indications, with the ultimate goal of providing patients greater access to more targeted treatments and appropriate clinical trials as quickly as possible. It is anticipated that the NGS test panel being developed may have the potential to receive simultaneous approval for several genes from the U.S. Food and Drug Administration and will be used as a CDx for multiple drugs.

GO AIM CONFERENCE CONVENES CANCER PATIENT ADVOCATES AND INDUSTRY

With scientific progress moving at an ever-accelerating pace, how can we ensure that the patient perspective and patient needs stay front and center? To find out, Pfizer hosted the Global Oncology Advocacy Innovators Meeting (GO AIM), a first-of-its-kind event that brought together cancer patient advocacy leaders from around the globe. Patient advocates shared with Pfizer that they are looking for a true partner. From helping to design clinical trials to educating policymakers on the value of potential new cancer innovations, patients and their advocates can provide important perspectives and direction at even the earliest stages of research and development.

“We are at a point where research is flourishing, and we are bringing new thinking and hope to cancer patients. However, we must not stop there. We must continue to innovate. Partnering with patient organizations is critical to further explore the needs of cancer patients around the world and together find potential solutions to address the challenges they face.”

— Albert Bourla, D.V.M., Ph.D.
Group President, Global Innovative Pharma and Global Vaccines, Oncology and Consumer Healthcare Businesses
Pfizer has signed on to the Dementia Discovery Fund, a new initiative that aims to boost investment in developing novel treatments for dementia. The fund is managed by SVLS Venture Partners and brings together Alzheimer’s Research UK, the U.K. government and six pharmaceutical companies (Pfizer, Biogen, GSK, Eli Lilly, Johnson & Johnson and Takeda) with the goal of financing early stage drug development projects. More than $100 million has already been raised to develop pioneering new medicines.

Neuroscience research has been a particularly challenging area for significant advances, due to the brain’s complexity. The science required to deeply understand its function is daunting and difficult. Yet we are seeing important scientific momentum in advances that are helping us unravel the underlying molecular disease pathophysiology of dementia and other neurological conditions. Cross-sector collaboration is a critical success factor to deliver unique and transformative potential therapies for patients.

“Because of the significant social, financial and scientific challenges that dementia-related illnesses pose, we believe that it will be most beneficial for patients if we create, identify and support innovative ways to partner with other pharmaceutical companies to help tackle dementia.”

— Douglas E. Giordano
Senior Vice President, Worldwide Business Development

47 MILLION
People in the world have dementia, at an estimated cost to the global economy of more than $604 billion a year, according to the World Health Organization.

3 PROGRAMS
In late-stage development in neuroscience and pain.

10 PROGRAMS
In phase 1 and phase 2 clinical trials in neuroscience and pain.

I’M WORKING ON...

Matt Howe
Postdoctoral Research Fellow, Neuroscience Research Unit

WATCH VIDEO
RESEARCH COLLABORATIONS

In our pursuit of science for life-changing impact, we collaborate on focused research programs to advance innovation quickly and effectively. Our research partners include academic institutions, foundations, government institutions, other biopharmaceutical companies and physicians — expanding the R&D ecosystem to better serve the needs of patients.

“We are working on identifying the best scientific expertise across the globe, and we are actively engaging in partnerships to leverage that expertise in mutually beneficial ways. It is imperative that we stay on the leading edge of science to deliver the most impactful medicines and vaccines to patients in need.”

— Dr. Uwe Schoenbeck
Senior Vice President and Chief Scientific Officer, External Research and Development Innovation
Our collaboration with Spark Therapeutics, Inc., has entered the clinic, testing with human subjects a potential gene therapy, SPK-FIX, for the treatment of hemophilia B. The U.S. Food and Drug Administration has designated this therapy an Orphan Drug. The investigational therapy incorporates a bio-engineered Adeno-Associated Virus (AAV) vector — in practical terms, a carrier for therapeutic genes. Such vectors use a disarmed virus redesigned with the genetic instructions to produce a missing enzyme or therapeutic protein. Advances in the technology to harness disarmed viruses as gene delivery vehicles, coupled with increased understanding of the biology of hereditary rare diseases, provide a ripe opportunity to investigate the next wave of potential life-changing therapies for patients.
23ANDME — FOCUS ON PATIENT COMMUNITIES GENERATING INSIGHTS

Our collaboration with 23andMe, Inc., a leading personal genetics company, enables us to study demographic and phenotypic data from nearly a million genotyped, de-identified individuals who have consented to participate in genetic research. Through this robust collaboration, we have been able to explore the links between genetic variation and disease phenotypes to identify new targets of potential therapeutic value. We believe this approach has strong potential for the future of drug discovery. In 2014, 23andMe and Pfizer combined forces to enroll 10,000 people with inflammatory bowel disease in a research initiative designed to explore the genetic factors associated with the onset, progression and severity of the disease, as well as response to treatments. In 2015, in a similar but more expansive effort, we collaborated with 23andMe to create a community for people with lupus, incorporating their medical records, genetic information and disease history to help better understand the etiology of the disease.

AARP® — PROJECT CATALYST HELPING DEVELOPERS IMPROVE HEALTH TECHNOLOGY FOR OLDER AMERICANS

Pfizer has teamed up with longtime partner AARP and other health care innovators on an AARP-led program to help technology product developers gain insights into how mature consumers use, or potentially could use, technology devices to improve and manage their health — a unique opportunity to help inform the design and usability of future products. “Project Catalyst — The Power of We” involves consumers aged 50+ in the innovation process by obtaining their feedback on product functionality and design as they incorporate new technology into their daily lives. The first studies have focused on tracking activity and sleep using wearable fitness trackers. Subsequent studies will focus on technology related to topics such as medication management and adherence, caregiving needs, and behavioral and emotional health.

“With the 50-plus population representing a large portion of the patients who depend on our medicines, we recognize the importance of finding innovative solutions to challenges such as medication management and adherence. Project Catalyst has the potential to enable collaboration across multiple stakeholder groups with the common goal of delivering valuable, innovative solutions.”

— Wendy Mayer
Vice President, Worldwide Innovation
PFIZER’S CENTERS FOR THERAPEUTIC INNOVATION

Our Centers for Therapeutic Innovation (CTI) continue to build on an open innovation model for collaborating with academic researchers, foundations and the U.S. National Institutes of Health (NIH). CTI is designed to bridge the gap between early scientific discovery and its translation into new medicines, with Pfizer scientists working side by side with researchers from academia. Currently, CTI has 34 projects ongoing across five therapeutic areas.

Pfizer Partnerships: Bringing the Best Minds Together

I’M WORKING ON...

Irina Apostolou
Director, Biology, Pfizer’s Centers for Therapeutic Innovation

Janet Buhlmann
Senior Principal Scientist, Immunology and Autoimmunity

CTI COLLABORATORS

25
ACADEMIC MEDICAL CENTERS

6
FOUNDATIONS

1
GOVERNMENT AGENCY
(THE U.S. NATIONAL INSTITUTES OF HEALTH)
NEW CTI COLLABORATIONS

The Alzheimer’s Drug Discovery Foundation

CTI’s collaboration with The Alzheimer’s Drug Discovery Foundation (ADDF) is designed to advance the development of potential new drugs for Alzheimer’s disease and related dementias. The collaboration allows investigators in CTI’s academic network to submit research proposals to be considered by CTI, in collaboration with Pfizer’s Neuroscience Research Unit and ADDF. Investigators whose proposals are selected receive joint funding from Pfizer and ADDF, as well as access to Pfizer’s unrivaled drug discovery resources and ADDF’s expertise in Alzheimer’s disease research.

Jeffrey Modell Foundation

The Jeffrey Modell Foundation (JMF), a foundation that honors Jeffrey Modell, a boy who died of complications from an immunological disease, is collaborating with CTI to advance therapies for patients like Jeffrey. His parents, Vicki and Fred Modell, founded JMF to champion and facilitate early diagnosis, meaningful treatment and, ultimately, cures for immunological diseases.

Creating a Single Pfizer Cambridge Campus

Pfizer has expanded a lease agreement with a Massachusetts Institute of Technology subsidiary for the Kendall Square Research Facility, enabling us to consolidate our Cambridge research centers to create a single Pfizer Cambridge campus. This should allow for stronger collaborations in the Boston/Cambridge bioscience community and open new doors to unique partnerships, in the interest of expediting discovery and development efforts in this hub of life science innovation.
CREATIVE COLLABORATION THAT PRESERVES THE CULTURE OF OUR BIOTECH PARTNERS

We continue to find creative ways to collaborate with innovators in biotech and biopharma that allow both sides to work together to accelerate the pace of innovation. This includes structuring relationships such that our collaborators are able to continue their efforts as they have been, but with access to resources of a leading, global health care company.

**AM-Pharma — Taking an Equity Stake in Innovation**

Pfizer acquired a minority equity interest in AM-Pharma B.V., a privately held Dutch biopharmaceutical company, and secured an exclusive option to acquire the remaining equity in the company. The arrangement allows the companies to leverage certain Pfizer resources that could potentially enable faster clinical development. AM-Pharma is focused on the development of recombinant human alkaline phosphatase (recAP) for inflammatory diseases — and is currently running a Phase 2 trial of recAP in the treatment of acute kidney injury related to sepsis. Pfizer’s option becomes exercisable upon completion of the Phase 2 recAP trial, and until such time, AM-Pharma remains responsible for all aspects of the execution and analysis of the study. There are no drugs currently approved for this condition.

**Heptares® — Gaining Access to StaR® Technologies**

Pfizer has entered into a strategic drug discovery collaboration with Heptares Therapeutics to research and develop potential new medicines directed at up to ten G protein-coupled receptor (GPCR) targets across multiple therapeutic areas. Heptares will use its proprietary GPCR structure-guided platform to help deliver stabilized GPCRs (StaR® proteins), high resolution crystal structures and other technologies to support the discovery of potential novel agents directed to the GPCR targets selected by Pfizer. Pfizer will be responsible for developing and commercializing any potential therapeutic agents (small molecules or biologics derived from StaR technology) for each target and will have exclusive global rights to any potential resulting agents. Heptares is a wholly owned subsidiary of Sosei, a global biopharmaceutical company based in Japan. In addition to the collaboration agreement, our Japanese subsidiary Pfizer Seiyaku KK has made an equity investment in Sosei.

**Gliknik® — Licensed Biologic Receives Orphan Drug Designation**

In August 2015, Orphan Drug status was granted by the U.S. Food and Drug Administration to GL-2045, a recombinant intravenous immuno-globulin mimetic licensed by Pfizer from Gliknik Inc., a privately held biopharmaceutical company, for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare neurological disorder. The designation makes available numerous incentives to develop the autoimmune drug candidate to address an unmet need. As a recombinant (not blood derived) biologic, it is hoped that GL-2045 may eventually provide patients an alternative that is at least as effective as blood-derived intravenous immunoglobulin therapies that others are developing.

**Evotec® — New Approaches for Potentially Treating Multi-Organ Fibrosis**

Pfizer and German biotech Evotec AG are collaborating to explore potential novel mechanisms for treating multi-organ fibrosis. The four-year license and collaboration agreement will see Evotec contribute its drug discovery platform while Pfizer will provide key technologies and industrial scope as well as pharmaceutical development and marketing expertise. Fibrosis is a non-physiological wound healing process that can lead to scarring and ultimately organ failure.
At Pfizer, we believe that all individuals deserve access to quality health care and the opportunity to lead healthy lives. We combine traditional philanthropic methods with novel approaches that create an enduring and meaningful impact on public health systems to facilitate access to health care for underserved communities around the world. This includes working in partnership with multilateral aid organizations, non-governmental organizations, government agencies and other global health stakeholders to address the complex challenges around improving health for the underserved.

“We’re working on making sure that more people than ever have access to our innovative medicines and vaccines. With an accountability mindset, where each colleague is committed to success and seizes opportunities to deliver value, we believe we will see great business results and meet the needs of our patients and society.”

JONATHAN EMMS
SENIOR VICE PRESIDENT AND HEAD, GLOBAL HEALTH & VALUE
Gavi, the Vaccine Alliance, through its Advanced Market Commitment, provides vaccines to the world’s poorest countries on an accelerated, affordable and sustainable basis. Pfizer has committed to supply up to 740 million doses of Prevenar 13® (pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed) through 2025. Prevenar 13 is available in more than 40 Gavi-eligible countries, with additional launches planned. We are committed to helping meet the Advanced Market Commitment’s primary goal of reducing morbidity and mortality from pneumococcal disease and, specifically, to prevent an estimated seven million childhood deaths by 2030.

**PROTECTING CHILDREN WORLDWIDE**

<table>
<thead>
<tr>
<th>THE NEED</th>
<th>PFIZER’S RESPONSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>~14.5M children are affected by pneumococcal disease each year.</td>
<td>100+ countries include Pfizer’s pneumococcal conjugate vaccine in their National Immunization Plans.</td>
</tr>
<tr>
<td></td>
<td>5 years 2015 marked five years of the Pfizer-Gavi partnership.</td>
</tr>
<tr>
<td></td>
<td>740M doses of Prevenar 13® pledged through Gavi, to immunize infants and young children in the world’s poorest countries through 2025 at the lowest price available.</td>
</tr>
<tr>
<td></td>
<td>$3M provided by The Pfizer Foundation in 2014 for pilot programs to enhance immunization coverage in Ethiopia, Malawi, Indonesia, Pakistan, Uganda and Zambia — focused on improving the “last mile,” the final step of the journey to bring vaccines to underserved infants and children.</td>
</tr>
</tbody>
</table>

(1) The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.
Addressing the specific family planning needs of women in the developing world is a key priority for Pfizer. Through tremendous efforts and ongoing key collaborations, we have made great progress in bringing our injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), to thousands of women living in the developing world.

In late 2014, Pfizer entered into a collaboration with the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation to help broaden access to Sayana Press for women most in need in 69 of the world’s poorest countries. The agreement is supported by a consortium of private sector donors and aid organizations, which include PATH, the United Kingdom’s Department for International Development, the United Nations Population Fund and the U.S. Agency for International Development. Through this collaboration, Sayana Press is being sold for US$1 per dose to qualified purchasers in selected countries, which helps enable the poorest women in these countries to have access to the contraceptive at reduced or no cost.

Sayana Press combines a long-acting, reversible contraceptive with an all-in-one prefilled, single-use, non-reusable Uniject™ injection system, eliminating the need to prepare a needle and syringe. Injectable contraceptives are a widely used family planning method, particularly among women in developing countries. They are discreet, eliminate the need for a daily pill regimen and, for some women living in remote areas, they can alleviate the deterrent of having to frequently travel long distances to get to a clinic. Accordingly, experts have identified the need for a contraceptive method that can be administered in low resource, non-clinic settings.
**SAYANA PRESS AVAILABLE IN U.K. FOR ADMINISTRATION BY SELF-INJECTION**

Building on momentum towards broadening access to this contraceptive option for women across the globe, Sayana Press is the first injectable contraceptive in the United Kingdom available to women for administration by self-injection when considered appropriate by a health care professional. This new method of administration is also approved in additional European Union markets, including Austria, Belgium, Hungary and The Netherlands. We will continue our efforts to help bring this updated label to more countries across the globe, with an initial focus on those in the developing world — such as Burkina Faso, Senegal and Uganda — where data show unmet need and demand for injectable contraceptives. Sayana Press is not yet approved for self-injection outside of the EU.

---

**WIPO RE:SEARCH**

To address the gap in early stage neglected tropical disease research, the World Intellectual Property Organization (WIPO), BIO Ventures for Global Health (BVGH), and the biopharmaceutical industry came together in 2011 to develop WIPO Re:Search — a creative platform dedicated to developing new solutions, including medicines, vaccines and diagnostics, for neglected tropical diseases, as well as malaria and tuberculosis. With over 100 members from 27 countries, the consortium has facilitated over 95 partnership agreements and has arranged various research sabbaticals whereby scientists from both developed and developing countries are hosted by members of WIPO Re:Search to learn from world-class laboratories. As a founding member of WIPO Re:Search, Pfizer continues to play a leading role and is involved in several agreements where we are making specific contributions to advance external research programs targeting tuberculosis, acute diarrhea, liver stage malaria, cerebral malaria, leishmaniasis, lymphatic filariasis and fascioliasis.